Long-Term Outcomes by Clopidogrel Duration and Stent Type in a Diabetic Population With De Novo Coronary Artery Lesions
Somjot S. Brar, MD*,*,
John Kim, MD ,
Simerjeet K. Brar, BS,
Ray Zadegan, MD,
Michael Ree, BS,
In-Lu A. Liu, MS ,
Prakash Mansukhani, MD,
Vicken Aharonian, MD,
Ric Hyett, BS and
Albert Yuh-Jer Shen, MD,
* Center for Interventional Vascular Therapy, Columbia University Medical Center, New York, New York
Department of Cardiology, Kaiser Permanente, Los Angeles, California
Department of Research and Evaluation, Kaiser Permanente, Pasadena, California
University of California, Los Angeles School of Medicine, Los Angeles, California.
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Outcomes by Stent Type
Cumulative incidence of death and nonfatal myocardial infarction or death only by stent type for the full cohort (n = 749). BMS = bare-metal stent(s); DES = drug-eluting stent(s).
|
|
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Left-Censored Survival Analysis for Death and Nonfatal Myocardial Infarction
Cumulative rates of death and nonfatal myocardial infarction by stent type and clopidogrel use in the left-censored survival analysis. Abbreviations as in Figure 1.
|
|
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Outcomes by Clopidogrel Duration
(A and B) Cumulative incidence of death and nonfatal myocardial infarction or death only by clopidogrel duration for the full cohort (n = 749). (C and D) Cumulative incidence of death and nonfatal myocardial infarction or death only by clopidogrel duration in the left-censored analysis.
|
|
|
